The Canadian government's treatment of scientific process and evidence: inside the evaluation of North America's first supervised injecting facility.

The Canadian government's treatment of scientific process and evidence: inside the evaluation of North America's first supervised injecting facility. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

The Canadian government's treatment of scientific process and evidence: inside the evaluation of North America's first supervised injecting facility. Abstract Text:

Although the recommendations of scientific review bodies have traditionally been free of political interference in Canada, there have recently been growing concerns raised about Canada's new federal government's treatment of scientific processes and evidence. This concern is relevant to the scientific evaluation of Canada's first medically supervised safer injecting facility (SIF), which opened in Vancouver in 2003, where illicit injection drug users can inject pre-obtained illicit drugs under the supervision of nurses. This commentary describes what may be a serious breach of international scientific standards relating to the Canadian government's handling of the SIF's scientific evaluation, and the circumstances which eventually led to a moratorium on SIF trials in other Canadian cities. Although the primary focus of this discussion should remain on the health of the people using the SIF, it is hoped that the publication of the information contained in this report will lead to greater public scrutiny of the Canadian government's handling of addiction research and drug policy, and provide lessons for researchers, drug policy-makers, and affected communities in other settings.

The Canadian government's treatment of scientific process and evidence: inside the evaluation of North America's first supervised injecting facility. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

The Canadian government's treatment of scientific process and evidence: inside the evaluation of North America's first supervised injecting facility. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: The International journal on drug policy

VOLUME: 19

Page Numbers: 220-5

Journal Abbreviation: Int. J. Drug Policy

ISSN: 1873-4758

DAY: 11

MONTH: Jun

YEAR: 2008

The Canadian government's treatment of scientific process and evidence: inside the evaluation of North America's first supervised injecting facility. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9014759

The Canadian government's treatment of scientific process and evidence: inside the evaluation of North America's first supervised injecting facility. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: The Canadian government's treatment of scientific process and evidence: inside the evaluation of North America's first supervised injecting facility. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for The Canadian government's treatment of scientific process and evidence: inside the evaluation of North America's first supervised injecting facility.

AFFILIATION: British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Vancouver, Canada. uhri@cfenet.ubc.ca

Country: Netherlands

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Int J Drug Policy

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

The Canadian government's treatment of scientific process and evidence: inside the evaluation of North America's first supervised injecting facility Related Publications

• A large prospective study assessing injection site reactions, quality of life and preference in patients using the Biojector vs standard needles for enfuvirtide administration.
• A review of barriers and facilitators of HIV treatment among injection drug users.
• Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy.
• Baseline viral load and immune activation determine the extent of reconstitution of innate immune effectors in HIV-1-infected subjects undergoing antiretroviral treatment.
• Cholesterol measured before stroke thrombolysis is not associated with tissue plasminogen activator related hemorrhagic transformation.
• Directly observed therapy programmes for anti-retroviral treatment amongst injection drug users in Vancouver: access, adherence and outcomes.
• Early and delayed benefits of HIV-1 suppression: timeline of recovery of innate immunity effector cells.
• Ethical and scientific issues surrounding solid organ transplantation in HIV-positive patients: Absence of evidence is not evidence of absence.
• Fas system activation in perihematomal areas after spontaneous intracerebral hemorrhage.
• Genetics of stroke: a review of recent advances.
• Highly active antiretroviral therapy and survival in HIV-infected injection drug users.
• Impact of HIV testing on uptake of HIV therapy among antiretroviral naive HIV-infected injection drug users.
• Increased soluble vascular cell adhesion molecule-1 plasma levels and soluble intercellular adhesion molecule-1 during antiretroviral therapy interruption and retention of elevated soluble vascular cellular adhesion molecule-1 levels following resumption
• Is nevirapine-based therapy discontinuation in hepatitis C co-infected patients a more important mortality determinant than hypersensitivity: authors' reply.
• MMP-9-positive neutrophil infiltration is associated to blood-brain barrier breakdown and basal lamina type IV collagen degradation during hemorrhagic transformation after human ischemic stroke.
• Microarray data on gene modulation by HIV-1 in immune cells: 2000-2006.
• Moderate and severe traumatic brain injury induce early overexpression of systemic and brain gelatinases.
• NK cell lysis of HIV-1-infected autologous CD4 primary T cells: requirement for IFN-mediated NK activation by plasmacytoid dendritic cells.
• Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen.
• Progression of symptomatic intracranial large artery atherosclerosis is associated with a proinflammatory state and impaired fibrinolysis.
• Rates of HIV/AIDS care and antiretroviral therapy response among active injection drug users.
• Should active recruitment of health workers from sub-Saharan Africa be viewed as a crime?
• Tenofovir-based rescue therapy for advanced liver disease in 6 patients coinfected with HIV and hepatitis B virus and receiving lamivudine.
• The Canadian government's treatment of scientific process and evidence: inside the evaluation of North America's first supervised injecting facility.
• The use of highly active retroviral therapy to reduce HIV incidence at the population level.
• Tissue plasminogen activator (t-PA) promotes neutrophil degranulation and MMP-9 release.
• Transmission of drug-resistant HIV-1 from an infected individual to a caregiver.
• [Biological markers in spontaneous intracerebral hemorrhage]
• [Commentary] ANTIRETROVIRAL THERAPY: A KEY PART OF THE PUBLIC HEALTH RESPONSE TO INJECTION DRUG USE.
• [The therapeutic potential of endothelial progenitor cells in ischaemic stroke.]